Answers are grounded in this paper and cite their sources.
Background: To evaluate the efficacy of peri-urethral thrombin instillation at the surgical site after trans-urethral prostate surgery in benign prostatic hyperplasia (BPH), with the objective of reducing post-operative hematuria and preserving voiding function.Methods: The study was retrospectively analyzed a total of 122 patients who had trans-urethral prostate surgery between January 2019 and March 2023.Among these, 33 received thrombin instillation, while 89 did not receive it.In the test group, a mixture of 5 cc of saline solution and 5,000 IU of thrombin was instilled below the balloon, targeting the surgical site by inserting a 5 Fr feeding tube along with the Foley catheter.We compared hematologic data and uroflowmetry (UFM) between pre and post-operative periods, the duration of continuous bladder irrigation (CBI) and Foley catheter indwelling period.Results: The mean age and prostate size in the test group were 71.52±7.15years and 54.05±24.73g, while 71.38±8.22 years and 64.52±28.43g in the control group.The prostate resected weight was 24.97±15.77g and 27.58±17.00g respectively.The hemoglobin and platelet levels were -1.05±0.81g/dL and -42.79±35.59×10 3 /L in the test group, and -1.08±0.97g/dL and -27.93±40.49×10 3 /L, in the control group.The test group showed better outcomes in CBI application time (21.31±12.15hours) and Foley catheter indwelling time (50.97±14.63hours) compared to the control group (34.42±22.68hours and 70.33±33.95hours) (P<0.001).Conclusion: After trans-urethral prostate surgery, thrombin agent instillation can prevent post-operative hematuria and facilitate quicker recovery to daily activities.
No takes yet. Share an insight, caveat, or question.
Sung et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: